Totally, isocitrate dehydrogenase (IDH) mutation tests were performed in 108 glioma specimens; 98 specimens underwent MGMT promoter methylation measurements; 74 specimens had 1p/19q codeletion analysis. This evidence concerns the gene IDH3A and central nervous system cancer.